Real-time vascular imaging and photodynamic therapy efficacy with micelle-nanocarrier delivery of chlorin e6 to the microenvironment of melanoma

Lee, Chien-Hsing; Lai, Ping‐Shan; Lu, Yen-Pei; Chen, Hsuan-Ying; Chai, Chee‐Yin; Tsai, Rong‐Kung; Fang, Kang-Tang; Tsai, Ming-Hsien; Hsu, Chih-Yu; Hung, Chun-Cheng; Wu, Deng‐Chyang; Yu, Hsin‐Su; Chang, Chia-Wen; Tsai, Din-Ping

doi:10.1016/j.jdermsci.2015.08.005

Cited by 21 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another approach is active targeting of the PS to tumour vascular endothelial markers such as EGFR, SST2R, αvβ3 integrin and neuropilin-1 39 40 . The use of chlorin-based PS for the vascular-targeted PDT was previously reported 41 42 ; however, to the best of our knowledge, vascular mechanisms of PDT with Photoditazin have never been explored. We have, however, previously characterized its pharmaco-kinetics and biodistribution in the bloodstream of tumour-bearing mice within 4 hours after i.v.…”

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy monitoring with optical coherence angiography

Sirotkina

Matveev

Shirmanova

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a promising modern approach for cancer therapy with low normal tissue toxicity. This study was focused on a vascular-targeting Chlorine E6 mediated PDT. A new angiographic imaging approach known as M-mode-like optical coherence angiography (MML-OCA) was able to sensitively detect PDT-induced microvascular alterations in the mouse ear tumour model CT26. Histological analysis showed that the main mechanisms of vascular PDT was thrombosis of blood vessels and hemorrhage, which agrees with angiographic imaging by MML-OCA. Relationship between MML-OCA-detected early microvascular damage post PDT (within 24 hours) and tumour regression/regrowth was confirmed by histology. The advantages of MML-OCA such as direct image acquisition, fast processing, robust and affordable system opto-electronics, and label-free high contrast 3D visualization of the microvasculature suggest attractive possibilities of this method in practical clinical monitoring of cancer therapies with microvascular involvement.

show abstract

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy monitoring with optical coherence angiography

Sirotkina

Matveev

Shirmanova

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The responsiveness of tumor to phototherapy has been monitored previously by neovasculature imaging 30 31 32 . The oxygen consumption and tumor hypoxia during PDT has also been characterized in vitro 33 34 35 .…”

Section: Discussionmentioning

confidence: 99%

Monitoring Tumor Hypoxia Using 18F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy

Tong

Srivatsan

Jacobson

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an efficacious treatment for some types of cancers. However, PDT-induced tumor hypoxia as a result of oxygen consumption and vascular damage can reduce the efficacy of this therapy. Measuring and monitoring intrinsic and PDT-induced tumor hypoxia in vivo during PDT is of high interest for prognostic and treatment evaluation. In the present study, static and dynamic 18F-FMISO PET were performed with mice bearing either U87MG or MDA-MB-435 tumor xenografts immediately before and after PDT at different time points. Significant difference in tumor hypoxia in response to PDT over time was found between the U87MG and MDA-MB-435 tumors in both static and dynamic PET. Dynamic PET with pharmacokinetics modeling further monitored the kinetics of 18F-FMISO retention to hypoxic sites after treatment. The Ki and k3 parametric analysis provided information on tumor hypoxia by distinction of the specific tracer retention in hypoxic sites from its non-specific distribution in tumor. Dynamic 18F-FMISO PET with pharmacokinetics modeling, complementary to static PET analysis, provides a potential imaging tool for more detailed and more accurate quantification of tumor hypoxia during PDT.

show abstract

“…In addition, the melanoma-specific antigen peptide, which is a melanoma-specific antigen delivered in a nanocarrier, can also activate specific cytotoxic T cells to achieve durable antitumor immunity. Furthermore, Chien et al developed a method for treating melanoma using the free form and micellar form of the PS CE6 in PDT [169]. Compared with the free CE6, the micellar nanocarrier attached CE6 had a clearer vascular image, and the micellar CE6 was localized in the lysosome and endoplasmic reticulum of cultured endothelial cells, suggesting active endocytosis of the nanocarrier.…”

Section: Nanoparticle-based Strategies For Melanoma Photodynamic Thermentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

Real-time vascular imaging and photodynamic therapy efficacy with micelle-nanocarrier delivery of chlorin e6 to the microenvironment of melanoma

Cited by 21 publications

References 31 publications

Photodynamic therapy monitoring with optical coherence angiography

Photodynamic therapy monitoring with optical coherence angiography

Monitoring Tumor Hypoxia Using 18F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Contact Info

Product

Resources

About